BMRA - Biomerica Inc

BMRA - Biomerica Inc

https://www.biomerica.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Kidney Test for Home Use

GlobeNewswire • 1 week, 5 days ago • score: 0.09

IRVINE, Calif., Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Biomerica, Inc. ( Nasdaq: BMRA ) , a global provider of advanced diagnostic solutions, announced today announced that the United Arab Emirates ( UAE ) Ministry of Health and Prevention has approved its Fortel® Kidney Test for home use.

United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Kidney Test for Home Use - Biomerica ( NASDAQ:BMRA )

Benzinga • 1 week, 5 days ago • score: 0.09

10-minute home test detects early kidney damage in diabetic and hypertensive patients Hypertension affects roughly one-third of adults in the UAE Diabetes impacts approximately one in four UAE nationals IRVINE, Calif., Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Biomerica, Inc.

Biomerica Reports Fiscal 2025 Year End Results

GlobeNewswire • 2 weeks, 2 days ago • score: 0.12

Biomerica 2025 Fiscal Year End Results ...

United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Ulcer Test for Home Use

GlobeNewswire • 1 month ago • score: 0.24

IRVINE, Calif., Aug. 14, 2025 ( GLOBE NEWSWIRE ) -- Biomerica, Inc. ( Nasdaq: BMRA ) , a global provider of advanced diagnostic solutions, today announced that the United Arab Emirates ( UAE ) Ministry of Health and Prevention has approved Biomerica's Fortel® Ulcer Test for home use.

United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Ulcer Test for Home Use - Biomerica ( NASDAQ:BMRA )

Benzinga • 1 month ago • score: 0.23

10-minute home test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancer H. pylori linked to approximately 80% of gastric cancer cases; classified as a Class 1 carcinogen by the World Health Organization

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$8.80

52W Low

$2.08

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.35

Valuation

As of 2025-05-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-5.42

EV/Revenue (<3 favorable)

1.09

P/S (TTM) (<3 favorable)

1.46

P/B (<3 favorable)

1.89

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

9.16%

Institutions (25–75% balanced)

3.38%

Shares Outstanding

2,815,400

Float

2,653,700

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-05-31 (Overview)

Revenue (TTM)

5,311,000

Gross Profit (TTM)

498,000

EPS (TTM)

-2.16

Profit Margin (>10% good)

-0.94%

Operating Margin (TTM) (higher better)

-2.09%

ROE (TTM) (>15% strong)

-0.93%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.33

Momentum

Bearish momentum

Value

-0.1224

Previous

-0.1301

Trend

Rising

Signal Cross

No cross

As of

Sep. 11, 2025